|Call us for Old-Fashioned Personal Service Toll-Free: 1-800-200-1203 Secure Online Shopping Since 1995|
In an Australian study conducted on injured soccer players, those that consumed Flavay® experienced significantly less swelling than those who did not.
Flavay® has been licensed and sold in France for treating inflammation and edema (swelling) since 1950 and is now available in the United States as a dietary supplement. Research shows several ways that Flavay® can help minimize damage and accelerate recovery time from strenuous workouts, sports-related activities and postoperative inflammation.
Flavay’s® action is synergistic for recovery from injuries: it prevents the overproduction of nitric oxide by the immune system and strengthens the bodys collagen, which is a major component of muscles, tendons, cartilage, ligaments and bones.
Flavay’s® ability to strengthen and rebuild collagen is important to injury-recovery because most athletic injuries involve damaged capillaries (tiny blood vessels), caused by torn muscles, sprains, fractures or twisting and whiplash. Strengthening of the vascular walls in the capillaries prevents fluids from seeping and swelling in the connective tissues. These types of injuries are painful and usually cause other problems, such as a loss in physical condition when the injury causes an inability to train or compete.
Research has shown that Flavay’s® ability to strengthen vascular walls may help the body to repair injuries faster. In an Australian study conducted on two groups of soccer players that had sustained injuries, those that consumed Flavay® for ten days following their injuries experienced significantly less swelling than those who did not and, in some of those taking Flavay®, the swelling had completely disappeared. Other research has demonstrated the ways in which Flavay® may actually inhibit inflammation including double-blind studies conducted in France which showed that Flavay® can also reduce postoperative inflammation.
Inflammation is caused by the overproduction of free radicals in a specific area of the body. We now know that antioxidants work together to defeat free radicals and inhibit the biological pathway that triggers inflammation, and Flavay® is particularly effective as an anti-inflammatory.
Flavay® can selectively bind to the connective tissue of joints, preventing inflammation and lessening pain. One of the very first benefits observed and studied Dr. Jack Masquelier, in as early as 1947, was the anti-inflammatory effect of Flavay®.
Research demonstrates that Flavay® inhibits the release and synthesis of histamine (which produces accelerated blood flow, dilates capillaries and increases their permeability, thereby leaking plasma into surrounding tissue), a key factor in the promotion of inflammation.
Studies demonstrate that the anti-histamine action of Flavay® is obtained through inhibiting the activity of the enzyme histidine decarboxylase. Dr. Masqueliers research has been confirmed by German studies which show that Flavay® may lower the production of histamine with as much as 86% inhibition of histidine decarboxylase.
Flavay® also neutralizes free radicals that promote swelling and cause inflammation. A free radical called superoxide is involved in the inflammation of arthritis and several experiments show that Flavay® quenches the superoxide free radicals.
Edema is an uncomfortable condition and can be both painful and dangerous. Swollen and painful legs and ankles, puffiness of the eyes and an overall bloated look and feel are examples of edema. It involves the leakage of blood serum into surrounding tissues and Flavay® has shown that it can reduce this leakage by strengthening capillary walls.
Italian scientists from the University of Florence studied the effect of Flavay® on venous congestion (edema) in the legs. The study involved 40 subjects consisting of 13 men and 27 women between the ages of 34 and 74. The subjects were randomly divided into two groups. One group received a placebo and the other group received 300 mg of Flavay® daily for 60 days.
All of those taking the Flavay® had relief from at least some of the symptoms. After 30 days, the pain was totally relieved in in 38 percent of those taking Flavay®, the swelling disappeared in 26 percent (the circumference of the legs was measured above the ankle), and 11 percent experienced a decrease in the feeling of heaviness in their lower limbs. After 60 days, the pain was totally relieved in 67 percent of those taking Flavay®, the swelling disappeared in 63 percent, and the decrease in heaviness jumped to 33 percent.
Flavay's® strong antioxidant power acts as a scavenger of the free radicals that play a major role in the initiation, duration and breakdown of inflammation.
Nitric Oxide: The Double-Edged Sword
Flavay® can significantly scavenge nitric oxide radicals. However, as we'll discuss next, your body needs a certain amount of nitric oxide in order to maintain good health. Nitric oxide is paradoxical. It can both mediate normal physiological functions and it can be highly toxic. Nitric oxide can act as an anti-inflammatory under normal health conditions, but it can have the opposite effect and cause more inflammation to an already inflamed area when overproduced. The key, therefore, is to maintain the optimum balance of this double-edged sword.
Nitric oxide is a colorless gas produced by many different cells in the body that, depending on the situation, can be very good or very bad. Nitric oxide plays several important roles in the body:
But nitric oxide can be very destructive under other circumstances:
The real trouble starts when nitric oxide encounters the superoxide free radical and becomes peroxynitrate, which destroys antioxidants like glutathione, vitamin E and common flavonoids, and damages proteins in the body. As long as nitric oxide is produced in the right amount, it remains friendly. But if nitric oxide is overproduced, the effect can be very toxic. Research demonstrates that Flavay® can help to maintain the optimal level of nitric oxide by helping the body to produce adequate levels—and to neutralize this free radical where it does harm.
Superior Antioxidant Support
Flavay® is superior to other antioxidants because its protective effects are multiplied in the body. While it provides its own, powerful antioxidant protection, it also supports the dynamic interplay between other antioxidants in the body. Flavay's ability to recycle, or regenerate vitamins C and E after they have quenched free radicals vastly extends their unique antioxidant powers, helping to maintain an optimal, synergistic antioxidant balance in the body.
Flavay® is rapidly absorbed and very quickly distributed throughout the body. As a free radical fighter, Flavay® comes to the aid of the body more quickly than other antioxidants, reducing the potential for free radical damage and the ravages of aging. Flavay® also possesses more reactive sites for neutralizing free radicals than other known antioxidants. Furthermore, Flavay® permits reactivity with both positively and negatively charged free radical species. What this means is that Flavay® can quench or scavenge (neutralize) a broad variety of free radicals. Highly reactive as an antioxidant in both lipid (fat) and aqueous (water) phases, Flavay® neutralizes oxygen free radicals and is a valuable protector of healthy cells in a variety of internal conditions. This is a unique property among antioxidants, as most work either in lipid or aqueous phases, but not both. Research shows that Flavay® can regulate nitric oxide and quench superoxide and the hydroxyl radical. This is extremely important. Of all the free radicals formed in the body, the hydroxyl radical is the most dangerous because it can directly attack DNA. As a free radical scavenger, Flavay® is like an antioxidant prize fighter that can successfully take on all challengers, big or small, in any kind of weather.
Call: 1-800-200-1203 or 210-481-0067 or Click for Email
Copyright © 1995-2015 Healthy Source, LLC. All rights reserved.
|Masquelier, J. A lifetime devoted to OPC and [pyc] [pyc]. Alfa Omega Editrice, Pub., 1996. Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice, Publishers, 1995. Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats Publishing, Inc., 1997. Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc., 1999. Packer, L., et al. Antioxidant food supplements in human health. Academic Press, 1999. Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease. Cambridge University Press, 1997. Moncada, S., Nistico, G., Bagetta, G., Higgs, E.A. Nitric oxide and the cell. Princeton University Press, 1998. Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats Publishing, Inc., 1985. Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants. Keats Publishing, Inc., 1995. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. Masquelier, J., et al. Stabilization du collagene par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981. Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969. Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978. Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977. Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de laction des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. Ii lattachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990. Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3, 4.4, 5.7-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17. Masquelier, J. Proanthocyanidins et radicaux libres. 1985. Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832. Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504. Da Silva, R., et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, Free radicals in biotechnology and medicine. Royal Society Of Chemistry, London January 1990, pp. 79-80. Bauman, J., Wurm, G., Bruchhausen, F. Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften Arch Pharm, (Weinheim) 313 (1980) pp. 330-337. Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998. Flesch M., et al., Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94. Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation and characterization of endothelium-dependent vasorelaxing compounds from grape seeds. J Agr & Food Chem In press. Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium, and wine. BioFactors 1997;6:455-459. Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol 1995;26:90-95. Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778. Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981. Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990. Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding of [pyc] to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33: 3933-3939, 1984. Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985. Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers extracted from vitus vinifera l. in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30. Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9. Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez lanimal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40. Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques chez lanimal-activite aniagoniste vis-a-vis des mediateurs de linflamation. Sanofi Res Toul Cedex Fr, pp. 31-40. Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par laction dune substance capillaro-toxique chez des personnes agees--action benefique dun agnet actif sur la micro-circulation: lEndotelon. Inform. Therapeut. 1980. pp. 302-305. Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude dun microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990. Lagrue, G., Olivier-Martin, F., Grillot, A. Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand lhypertension arterielle et certaines nephropathies. Sen. Hosp. Paris 18-25 Septembre, 1981. Beylot, C., Bioulac, P. Essai therapeutique dun angioprotecteur peripherique, lEndotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980. Lesbre, F.X., Tigaud, J.D. Effect de lEndotelon sur lindice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983. Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur lEndotelon. Bordeaux Med, 11:685-8, 1981. Delacroix, P. Etude en double aveugle de lEndotelon dans linsuffisance veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981. pp. 1793-1802. Thebaut, J.F, Thebaut, P., Vin, F. Etude de lEndotelon dand les manifestations fonctionnelles de linsuffisance veineuse peripherique-resultats dune etude en double aveugle portant sur 92 patients. Gazette Medicale, (92)1, 1985. pp. 96-100. Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989. Masquelier, J. [pyc]: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256. Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106. Masquelier, J. Les procyanidols du vin leur role dans lalcoolisme. pp. 88-93. Gazave, J.M. Notions recentes sur les capillaires unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29. Ruf, J.C. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999. Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980. Tayau, M.F, LeFevre, G. Action du leucocyanidol sur lhyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956. Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22. Henriet, J.P Une Etude Exemplaire Pour Un Phlebotrope: letude EIVE. Unpub., pp. 77-83. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237. Kuttan, R., Donnelly, P., Di Ferrante, N. Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase. Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980. Gendre, P., Laparra, J., Barraud, E. Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat. Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73. Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988. Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988. Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988. Saracco, J.B., Estachy, G.M. Etude d lEndotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981. Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981. Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988. Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978. Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987. Fromantin, M. Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas. Med Int, 16(11):432-434, Nov. 1981. Arne, J.L. Contribution a letude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982. Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984. Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981. Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983. Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977. Masquelier, J. Action protectrice du vin sur lulcere gastrique. Resultats, p. 61. Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985. Shaw, R. How [Australian] [pyc] [MASQUELIERs®] Helps Sports People. Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990. Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques de members superieurs. Symposium Satellite, Congres International dAngiologie, Toulouse, France, 4-7 Oct. 1989. Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks of intense training. Abstract submitted to national meeting of the Amer College of Sports Medicine, June 1998. Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm 43: 385388, 1992. Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine administration during two weeks of resistive exercise-induced overtraining. Bio of Sport 15(3):135-44, 1998. Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux, 1976. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur loxydation de lacide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur lacide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306 Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells. Chem. Pharm. Bull. 33(11)1985. 5079-5082. Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J. Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro. Dirkhauser Verlag,Vol. 7/1, 1977. Pariente, J.J. Parientl-Amsellem, J. Les oedemes post-traumatoqies chez le sportif: essai controle de lEndothelon. Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235. Masquelier, J., et al. Flavonoids et [pyc] Int J Vit Nut Res, (49)3:307-311, 1979. Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987. Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971. Laparra, J., et al., Acta Therapeutica, 4:233, 1978. Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with [pyc]. Cytotest Cell Research GmbH & Co., projects 143010 & 143021; Feb. 1989. Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover, Germany, 1967-1971. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.|